Top Industry Leaders in the Gitelman Syndrome Market
Latest Gitelman Syndrome Companies Updates:
BioMarin Pharmaceutical releases promising early data from a Phase 2 clinical trial of BMN-351, a novel investigational therapy aiming to address the underlying cause of Gitelman Syndrome by correcting the defective sodium chloride cotransporter.
Horizon Therapeutics receives FDA approval for Krystexxa® (burokalifex) extended-release tablets for treating hypokalemia (low potassium levels), a common symptom in Gitelman Syndrome.
AstraZeneca partners with academic institutions to conduct research on potential gene therapy approaches for Gitelman Syndrome, offering a future possibility for a one-time curative treatment.
The Gitelman Syndrome Foundation collaborates with pharmaceutical companies and research institutions to accelerate clinical trials and advance Gitelman Syndrome research.
List of Gitelman Syndrome Key companies in the market:
- Pfizer Inc. (U.S.)
- Hisoar (China)
- Taj Pharmaceuticals Ltd. (India)
- Merck & Co., Inc. (U.S.)
- Xinhua Pharm (China)
- BIOCAUSE Inc. (China)
- Thermo Fisher Scientific Inc. (U.S.)
- Bio-Rad Laboratories, Inc. (U.S.)
- F. Hoffmann-La Roche Ltd (Switzerland)
- QIAGEN (Germany)